113774-91-7

Basic information

• Product Name: Carbamic acid, (1-methyl-4-pentenyl)-, phenylmethyl ester, (R)-
• CAS NO: 113774-91-7
• Molecular Formula: C14H19NO2
• Molecular Weight: 233.31
• Mol File: 113774-91-7.mol

Chemical Properties

• CAS DataBase Reference: Carbamic acid, (1-methyl-4-pentenyl)-, phenylmethyl ester, (R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (1-methyl-4-pentenyl)-, phenylmethyl ester, (R)-(113774-91-7)
• EPA Substance Registry System: Carbamic acid, (1-methyl-4-pentenyl)-, phenylmethyl ester, (R)-(113774-91-7)

Safety Data

• Hazardous Substances Data: 113774-91-7(Hazardous Substances Data)

Upstream product

• 2622-05-1 allylmagnesium bromide 
• 113707-75-8 ((R)-2-Iodo-1-methyl-ethyl)-carbamic Acid Benzyl Ester 
• 113707-74-7 [(2R)-2-(benzyloxycarbonylamino)propyl] 4-methylbenzenesulfonate 
• 61425-27-2 ((R)-2-hydroxy-1-methyl-ethyl)-carbamic acid benzyl ester 

Downstream Products

• 362510-16-5 Allyl-((R)-1-methyl-pent-4-enyl)-carbamic acid benzyl ester 
• 138133-34-3 trans-(2S,5S)-2,5-dimethylpyrrolidine hydrochloride 
• 143064-43-1 (E)-(2S,5R)-1-(benzyloxycarbonyl)-2-(11-(benzyloxy)-3-oxo-1-undecenyl)-5-methylpyrrolidine 
• 143120-65-4 (Z)-(2S,5R)-1-(benzyloxycarbonyl)-2-(11-(benzyloxy)-3-oxo-1-undecenyl)-5-methylpyrrolidine 
• 135625-69-3 (E)-(2R,5S)-1-(benzyloxycarbonyl)-2-methyl-5-(3-oxo-1-decenyl)pyrrolidine 
• 143120-64-3 (Z)-(2R,5S)-1-(benzyloxycarbonyl)-2-methyl-5-(3-oxo-1-decenyl)pyrrolidine 
• 143064-44-2 (3R,5S,8S)-5-(8-(benzyloxy)octyl)-3-methylpyrrolizidine 
• 135625-68-2 (2S,5R)-2-Formyl-5-methyl-pyrrolidine-1-carboxylic acid benzyl ester 
• 135649-90-0 (2S,5R)-1-(benzyloxycarbonyl)-2-(hydroxymethyl)-5-methylpyrrolidine 
• 136522-02-6 (2S,5S)-2,5-dimethylpyrrolidine-1-carboxylic acid benzyl ester 

Relevant articles and documents

Protease inhibitors

The present invention provides C1-6alkyl-4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease; and parasitic diseases, including malaria, by administering to a patient in need thereof one or more compounds of the present invention.

Protease inhibitors

The present invention provides C3-C6 1-amino-1-acyl cycloalkane-substituted 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K,

Protease inhibitors

The present invention provides methods which use 4-amino-azepan-3-one protease inhibitors of cathepsin S in the treatment of diseases in which cathepsin S is implicated, especially treatment or prevention of autoimmune disease; treatment or prevention of a disease state caused by the formation of atherosclerotic lesions and complications arising therefrom; and diseases requiring inhibition, for therapy, of a class II MHC-restricted immune response, inhibition of an asthmatic response, inhibition of an allergic response, inhibition of immune response against a transplanted organ or tissue, or inhibition of elastase activity in atheroma, and novel compounds for use therewith.

THE SYNTHESIS OF EITHER (+) OR (-) TRANS-2,5-DIMETHYLPYRROLIDINE

Trans-2,5-dimethylpyrrolidine, in either optical series, is prepared starting from D or L-alanine in an efficient and reasonably brief reaction sequence.